About: fang

HONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – MODONG Coffee, a leading global health and wellness brand, is proud to announce its sponsorship of G-DRAGON 2025 WORLD TOUR [Übermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP, taking place on July 11 (Fri.) and July 13 (Sun.) at the Taipei Arena. As the Official Sponsor, MODONG Coffee brings an innovative fusion of “Music × MODONG Energy” to create an immersive audiovisual experience for fans. This collaboration marks a strategic milestone in MODONG Coffee’s youth-centric expansion, advancing its “IP + Scenarios + New Retail” ecosystem.As one of Asia's most influential music IPs, G-DRAGON’s upcoming tour, themed "Übermensch", symbolizes his groundbreaking interpretation of art and self-expression. As an Official Sponsor, MODONG Coffee joins forces with Samsung, ADATA Technology, and other brands to deliver an immersive experience, seamlessly blending stunning visuals with exceptional music for the audience. As the flagship product of Star Plus Legend's new retail business, MODONG Coffee has established a leading position in China’s bulletproof drink market since its launch in 2019 with its differentiated product positioning. According to China Insights Consultancy, MODONG coffee has ranked first in the bulletproof drink market by GMV in the PRC for five consecutive years (2020-2024). As of 2024, the cumulative sales of MODONG coffee have reached 100 million cups. That same year, MODONG brand and its products earned multiple prestigious certifications, including “a high profile brand in Jiangsu province” and “the iSEE list of top 100 innovative brands”, further solidifying its market competitiveness.Additionally, MODONG Coffee has deeply integrated with the phenomenal variety show IP "J-Style Trip", achieving "traffic-to-sales conversion" through celebrity-driven marketing and scenario-based campaigns. This strategy drove a 360% year-on-year sales surge in its debut year, propelling Star Plus Legend’s net profit to soar 233% YoY. To meet evolving consumer demands, MODONG Coffee underwent a brand upgrade in 2025, launching the MODONG MAGIC series—Sicilian Lemon Coffee and Cactus Black Coffee—under the concept "A Cup On-the-Go: Crafting Magic for Healthy Living". The brand aims to pioneer a new MODONG lifestyle rooted in low-carb diets and scientific fitness, fostering healthier habits and redefining the relationship between nutrition and wellness. To amplify brand influence, MODONG MAGIC became the exclusive title sponsor of "J-Style Trip Season 3". The show has aired nine episodes to date, dominating CSM71-city provincial satellite TV ratings with nine consecutive time-slot No.1 rankings. It generated 298 trending topics and over 2.9 billion impressions across platforms, igniting widespread social engagement. The support for the "G-DRAGON 2025 WORLD TOUR [Übermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" represents a key step in MODONG Coffee’s strategic layout of combining “healthy trendy beverages + entertainment.” By leveraging G-DRAGON's global fan appeal and the high popularity of the concert, the brand aims to further expand its influence in the Asia-Pacific market — marking a significant leap for MODONG Coffee from product to brand, and from local to global.Looking ahead, MODONG will remain sharply focused on Gen Z consumers, engaging them through health, music, fashion, and digital art to strengthen its youth-oriented identity. Powered by AI-driven IP innovation, the brand is poised to accelerate the fusion of digital technology and the real economy. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Highlights- Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune disease- Milder T cell activation than Blincyto and Target cell-dependent T cell activation- Multiple CR cases observed in ongoing r/r NHL Phase Ia trial and r/r ALL Phase Ib/II trialHONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – Excyte, a global clinical-stage biotechnology company, announced first patient has been dosed for YK012, the world’s first patient T cell engager that entered into clinical trial for primary membranous nephropathy (pMN). The patient remained well after administration with no adverse reactions witnessed to date.pMN is an autoimmune disease caused by the attack of autoantibodies against podocyte antigens leading to the in situ production of immune complexes. pMN is the most common cause of primary nephrotic syndrome in non-diabetic adults worldwide, accounting for 20% to 37% of affected individuals, and as high as 40% in adults over 60 years of age (1). Currently, 20-30% of pMN cases are resistant to current therapies like rituximab and cyclophosphamide and relapse rates can be high (2).A clear regulatory pathway in this orphan disease in US could make YK012 one of the first approved TCE in the autoimmune space with many other autoimmune and oncology indications to follow. Excyte would file for US investigational new drug (IND) application imminently.The study aims to evaluate the safety, tolerability, and preliminary efficacy of YK012 in PMN patients. Led by Professor Minghui Zhao and Prof Zhao Cui from Peking University First Hospital, the trial is planned to be conducted across multiple centers in China. The clinical trial for this indication in the United States will be collaboratively executed by Excyte and its international partners.“YK012 is a T-cell engaging bispecific antibody targeting both CD19 and CD3, activating T-cell immunity via CD3 while targeting CD19—the most widely expressed tissue-specific marker during B-cell development and thereby enabling B-cell reset. Our data illustrated YK012 mediated significant B cell depletion and have illustrated in current clinical studies extended half-life and limited cytokine release in patients,” said Mr. Andrew Meng, chairman and COO at Excyte. “We look forward to collaborating with regulatory authorities to make YK012 available to this  patient population with a high unmet medical need."In December 2024, YK012 obtained Clinical Trial Approval Notice (No. CXSL2400727) from China's National Medical Products Administration (NMPA) and was registered on ClinicalTrials.gov (NCT06982729). With the first patient dosed in pMN, Excyte now has a global presence in autoimmune diseases in additional to oncology indications such as NHL and ALL. Earlier this year, Excyte also secured clinical trial approval for systemic lupus erythematosus (SLE), with Professor Xiaofeng Zeng from Peking Union Medical College Hospital serving as Principal Investigator.About Excyte Biopharma Ltd.Excyte Ltd. was co-founded by Dr Qing’an Yuan and Mr Andrew Meng , biotech industry veterans with decades of antibody engineering experiences. The company has also established a U.S.-based wholly-owned subsidiary, Excyte LLC, forming a dual-engine drug R&D hub spanning China and the U.S. Excyte is dedicated to developing innovative bispecific antibody drugs for hematologic cancers, multiple myeloma, solid tumors, autoimmune diseases, and other conditions. Excyte’s FIST platform and next generation assets possess features such as long-acting, low-toxicity, and high-yield technological innovations. For more information, please visit https://www.iExcyte.com/Business Development ContactYing Liu, liuying@iExcyte.comReferences:1.William G Couser, Primary Membranous Nephropathy, Clin J Am Soc Nephrol. 2017 May 26;12(6):983–997.2.Elham Ahmadian, Seyed Mahdi Hosseiniyan Khatibi, Sepideh Zununi Vahed, Mohammadreza Ardalan, Novel treatment options in rituximab-resistant membranous nephropathy patients, International Immunopharmacology, Volume 107, 2022, 108635, ISSN 1567-5769. Copyright 2025 ACN Newswire via SeaPRwire.com.

BANGKOK, May 28, 2025 - (ACN Newswire via SeaPRwire.com) - Sappe PCL (SAPPE), a pioneer in beverage innovation from Thailand that has gained recognition among consumers worldwide, is set to reinforce its global brand ambition at THAIFEX – ANUGA ASIA 2025, Asia’s premier food and beverage trade exhibition. The event will take place from May 27–31, 2025, at Booth 1-QQ01, Impact Challenger Hall 1, Muang Thong Thani, Bangkok, Thailand.The highlight of this year’s showcase is the official launch of Mogu Mogu’s new global campaign, “Life’s too Short, You Gotta Chew” presenting the world’s first Snackable Drink, a category created by SAPPE itself. The campaign marks a major milestone in reshaping the global beverage experience by blending taste, texture, and lifestyle in one fun and refreshing product.Mission to Mars: A Thai Brand Journey to the Future of Global GrowthUnder the concept of “Mission to Mars,” SAPPE’s exhibition booth is designed to resemble a spacecraft transporting over 10 beverage brands from Thailand on a journey into the future. The concept symbolizes bold creativity, forward thinking, and the ambition to share Thai-made innovations with consumers worldwide.Featured products include Mogu Mogu, Sappe Aloe Vera, Sappe Beauti, and the company’s newest innovations designed with a strong focus on quality, taste, functionality, health benefits, and environmental responsibility, to meet the evolving preferences of today’s global consumers.Mogu Mogu: Turning Ordinary Days into Chewable FunThe “Life’s too Short, You Gotta Chew” campaign makes its global debut at the event, supported by three vibrant new TV commercials. The campaign highlights Mogu Mogu’s playful, upbeat personality and connects with today’s young consumers who seek Social Connection, FOMO (Fear of Missing Out), Instant Gratification, and a lifestyle filled with fun and spontaneity.SAPPE is working with key partners in major international markets including South Korea, Philippines, France, and the United Kingdom to expand the campaign’s global reach and deepen engagement with Mogu Mogu’s growing fan base. The company aims to significantly increase international brand engagement by the end of this year.Beyond Export: SAPPE’s Vision to Build a Lasting Global BrandMs. Piyajit Rackariyapong, Chief Executive Officer of SAPPE, said:“We don’t just export beverages. Our mission is to build a brand from Thailand that leads with innovation, offers new excitement and drinking experiences to consumers, and brings positivity into people’s everyday lives.”SAPPE’s consistent participation in THAIFEX – ANUGA ASIA for over a decade reflects the company’s commitment to becoming a creative force in the global beverage industry driven by bold ideas, cultural connection, and consumer empathy.THAIFEX – ANUGA ASIA: A Global Value Chain GatewayOrganized by Thailand’s Department of International Trade Promotion (DITP) in partnership with the Thai Chamber of Commerce and Koelnmesse Germany, THAIFEX – ANUGA ASIA serves as a critical platform for Asian food and beverage brands to connect with the global value chain. SAPPE continues to be one of the most prominent Thai brands recognized annually on this stage.Visit SAPPE at Booth 1-QQ01, IMPACT Challenger Hall 1, Muang Thong Thani, Bangkok, Thailand, throughout the 5-day event. Follow Mogu Mogu’s global journey at www.mogumogu.comAbout SAPPESappe Public Company Limited (SAPPE) is a leading Thai beverage innovator and the owner of several iconic brands. The company specializes in fruit juice and functional drinks, developed to serve the modern lifestyle of consumers across global markets. SAPPE currently exports to over 100 countries worldwide, with a strong presence in Asia, Europe, and the Middle East.Its portfolio includes globally recognized brands such as Mogu Mogu, the world’s first Snackable Drink; Sappe Aloe Vera, known for its refreshing taste and natural ingredients; and Sappe Beauti, a health-focused functional drink line. SAPPE is headquartered in Bangkok, Thailand, and is listed on the Stock Exchange of Thailand (SET) under the symbol SAPPE.Driven by innovation, consumer insights, and sustainability, SAPPE is committed to delivering high-quality products that bring joy, well-being, and new experiences to people around the world.Sappe official: https://www.sappe.com/en/Facebook:  https://www.facebook.com/sappeplaygroundInstagram:  https://www.instagram.com/mogumogu_global/Line:  https://shop.line.me/@sappeonlineShopee:  https://shopee.co.th/sappe.officialEmail: corpcom@sappe.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Highlights Financing included an upsized C$9.8 million (A$10.8 million) Private Placement and an oversubscribed A$1.5 million (C$1.4 million) Share Purchase PlanCompany welcomes the European Bank of Reconstruction and Development and Eric Sprott as significant shareholdersFunds raised to support ongoing development of the Chvaletice Manganese Project and customer engagements to secure additional offtake term sheets and strategic investmentsVancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 28, 2025) - Euro Manganese Inc. (TSXV) (ASX: EMN) (FSE: E060) (the "Company" or "Euro Manganese") is pleased to announce that, following the approval by its shareholders at its Annual General and Special Meeting held on May 15, 2025 (the "AGSM"), it has closed the previously announced financing package which included: (a) a private placement (the "Placement") of common shares ("New Shares") and CHESS Depositary Interests ("New CDIs" together with the New Shares, "New Securities") in the capital of the Company of C$9.8 million (approximately A$10.8 million); and (b) a Share Purchase Plan ("SPP", together with the Placement, the "Financing") with certain eligible shareholders in the amount of A$1.5 million (approximately C$1.4 million). The Company also announces an option grant to certain directors, officers, employees, and consultants as described below.Martina Blahova, CEO of Euro Manganese, commented:"We are extremely pleased with the strong support demonstrated by both our existing shareholders and new investors, including the notable participation of Mr. Eric Sprott. As Euro Manganese's largest shareholder, EBRD's investment reinforces its support and commitment to the Chvaletice Project. This critical financing enables the Company to pursue certain key milestones and advance project development. We thank shareholders for their ongoing support."The net proceeds of the Financing will be used to support ongoing development of the Chvaletice Manganese Project, including customer engagements to secure additional offtake term sheets and strategic investments, the operation of the demonstration plant, as needed, to market the Company's product to potential customers and to advance permitting.All defined terms in this press release have the same meaning as set out in the press releases dated March 6, 2025 and April 1, 2025, unless such terms are otherwise defined herein.Details of the PlacementThe Placement consisted of the issuance of an aggregate of 54,578,350 New Securities, comprised of 39,671,662 New Shares at a price of C$0.18 per New Share and 14,906,688 New CDIs (with each New CDI representing one New Share) at a price of A$0.195 per New CDI, and 54,578,350 Warrants for aggregate gross proceeds of C$9.8 million (approximately A$10.8 million). Warrants issued in connection with the Placement are exercisable any time prior to November 28, 2026 (Vancouver), and have an exercise price of C$0.225 per New Security. Included in the Placement were:14,650,278 New CDIs and 14,650,278 Warrants subscribed for under the Placement led by the Joint Lead Managers (as defined below);39,463,331 New Shares and 39,463,331 Warrants subscribed for directly with the Company, which included (i) 21,400,000 New Shares and 21,400,000 Warrants subscribed for by the European Bank for Reconstruction and Development ("EBRD") (the "EBRD Subscription"); (ii) 16,666,666 New Shares and 16,666,666 Warrants subscribed for by Mr. Eric Sprott, through 2176423 Ontario Ltd., a corporation which is beneficially owned by Mr. Sprott; and (iii) 1,396,665 New Shares and 1,396,666 Warrants subscribed for by other, non-related investors; andsubscriptions by directors of the Company for 464,741 New Securities (comprised of 208,331 New Shares and 256,410 New CDIs) and 464,741 Warrants (the "Related Party Subscription").As the number of New Securities and Warrants issued under the Placement led by the Joint Lead Managers, pursuant to the EBRD Subscription, and subscribed for directly with the Company exceeded the number of securities permitted to be issued without obtaining prior shareholder approval under Listing Rule 7.1 of the Australian Securities Exchange ("ASX"), the Company was required to seek shareholder approval. Similarly, the Related Party Subscriptions were subject to shareholder approval as required by ASX Listing Rule 10.11.1 and 10.11.4. Resolutions approving these issues were sought and received at the AGSM.Since certain directors and management of the Company participated in the Placement, the Placement is considered to be a related party transaction subject to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(1)(a) of MI 61-101 on the basis that participation in the Placement by such directors and management does not exceed 25% of the fair market value of the Company's market capitalization, as calculated in accordance with MI 61-101.Details of the Share Purchase PlanThe SPP was conducted pursuant to a Prospectus dated April 23, 2025 and was comprised of 7,692,307 New CDIs at a price of A$0.195 per CDI, and 7,692,307 Warrants, for aggregate gross proceeds of A$1.5 million (approximately C$1.4 million). Warrants issued in connection with the SPP are exercisable any time prior to November 28, 2026 (Vancouver), with an exercise price of C$0.225 per New Security.As announced in the Company's news release of May 15, 2025, the SPP was oversubscribed and subscriptions were scaled back to the maximum aggregate amount permitted.As the number of New CDIs and Warrants issued under the SPP exceeded the Company's Placement Capacity under ASX Listing Rule 7.1, the Company was required to seek shareholder approval, such approval having been received at the AGSM.Broker Fees and Additional WarrantsCanaccord Genuity (Australia) Limited ("Canaccord Genuity") and Foster Stockbroking Pty Ltd ("FSB", together with Canaccord Genuity, the "Joint Lead Managers") acted as Joint Lead Managers and Bookrunners for the Financing. Aggregate fees payable in cash by the Company to Canaccord Genuity and FSB in connection with the Financing consisted of A$498,918 (approximately C$454,016).In addition, the Company also issued 4,904,478 broker warrants (the "Broker Warrants") to Canaccord Genuity and FSB, representing 12% of the aggregate number of New Securities issued under the Placement and the SPP, excluding those issued pursuant to the EBRD Subscription. The Broker Warrants are exercisable any time prior to May 28, 2027 (Vancouver), with an exercise price of C$0.225 per New Security.Additionally, as announced previously on March 6, 2025 and April 1, 2025, and in connection with an amendment to the Company's Convertible Loan Royalty Agreement (the "CLRA") with OMRF (BK) LLC ("Orion") the Company has issued 22,263,733 warrants to purchase New Securities (the "Additional Warrants") to Orion, exercisable any time prior to November 28, 2026 (Vancouver), with an exercise price of C$0.225 per New Security. Additional details about the CLRA are available in the news releases of the Company dated December 3, 2024, November 29, 2023 and November 27, 2023.As the number of the Broker Warrants and Additional Warrants exceeded the Company's Placement Capacity under ASX Listing Rule 7.1, the Company was required to seek shareholder approval, such approvals having been received at the AGSM.Applicable Hold PeriodsNew Shares issued or made issuable under the Financing will not be permitted to be traded in or into Canada or through the facilities of the TSX Venture Exchange (the "TSX-V") prior to a four month and one day statutory hold period expiring on September 29, 2025 (Vancouver), and will be subject to legending requirements under Canadian securities laws. New Shares will be listed on the TSX-V and New CDIs listed on the ASX. The Warrants, Broker Warrants and Additional Warrants will not be listed. New CDIs will not be permitted to be exchanged for common shares and traded through the facilities of the TSX-V prior to the four month and one day statutory hold period expiring on September 29, 2025 (Vancouver).The Warrants, Broker Warrants and Additional Warrants will not be listed. Common shares issued upon exercise of the Warrants, Broker Warrants or Additional Warrants prior to September 29, 2025 (Vancouver) are subject to the same restrictions noted above.The Warrants, Broker Warrants or Additional Warrants may not be traded in or into Canada prior to September 29, 2025 (Vancouver) and will be subject to legending requirements under Canadian securities laws.Early Warning Disclosure for The European Bank for Reconstruction and DevelopmentEBRD acquired the 21,400,000 units pursuant to the Placement at a price per unit of C$0.18 for total consideration of C$3,852,000.Prior to the completion of the EBRD Subscription, EBRD owned 3,560,000 common shares, representing an ownership interest of 4.42% of the issued and outstanding common shares of the Company. On completion of the EBRD Subscription, EBRD's ownership interest increased to 24,960,000 common shares, representing an ownership interest of 17.48% of the issued and outstanding common shares and an increase of 13.06%. Assuming the exercise by EBRD of all its Warrants, and assuming the exercise of (i) all Warrants issued under the Placement, (ii) all Warrants issued under the SPP, and (iii) all Additional Warrants, EBRD's ownership interest will be in aggregate 46,360,000 common shares, representing an aggregate beneficial ownership interest of 19.96% of the issued and outstanding shares and an increase of 15.54%. EBRD has agreed, pursuant to the terms of the Warrants issued to EBRD, that for so long as the Company is listed on the TSX-V, unless approval from the TSX-V and disinterested shareholders of the Company have been obtained pursuant to the policies of the TSX-V (provided that such approval is required at the relevant time), EBRD will not be permitted to exercise such number of warrants that would result in it beneficially owning more than 19.99% of the outstanding common shares of the Company.EBRD acquired the New Shares and Warrants for investment purposes. Depending on market conditions and other factors, EBRD may from time to time acquire and/or dispose of securities of the Company or continue to hold its current position.To obtain a copy of the early warning report to be filed by EBRD in connection with this press release, please contact: Michael Zlobin at +44 207338 8981. EBRD's address is 5 Bank Street, London, E14 4BG, United Kingdom.Early Warning Disclosure for Eric SprottEric Sprott, through 2176423 Ontario Ltd., a corporation that is beneficially owned by him acquired 16,666,666 units pursuant to the Placement, at $0.18 per unit for total consideration of C$3,000,000. Prior to the Placement, Mr. Sprott did not beneficially own or control any securities of the Company. As a result of the Placement, Mr. Sprott now beneficially owns 16,666,666 Shares and 16,666,666 Warrants, representing approximately 11.7% of the outstanding Shares on a non-diluted basis and 20.9% of the outstanding Shares on a partially-diluted basis assuming exercise of such Warrants.The securities are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities including on the open market or through private acquisitions or sell the securities including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.A copy of the early warning report with respect to the foregoing will appear on Euro Manganese's profile on SEDAR+ at www.sedarplus.ca and may also be obtained by calling Mr. Sprott's office at (416) 945-3294 (2176423 Ontario Ltd., 7 King Street East, Suite 1106, Toronto Ontario M5C 3C5).Option GrantThe Company today also granted stock options ("Options") to certain of its directors, officers, employees, and consultants to purchase up to an aggregate of 7,020,000 common shares ("Shares"). Of these, 1,330,000 Options have been granted to directors, 2,530,000 Options have been granted to officers, and 3,160,000 Options have been granted to employees and consultants. The Options are exercisable for a term of ten years at an exercise price of CAD$0.19 per Share. All of the Options will vest one-third immediately and then one third on each of the first and second anniversaries of today's date of grant, except that 1,650,000 of the Options granted to certain officers, employees and consultants will all vest immediately in recognition of such individuals work in managing the successful completion of the oversubscribed Financing.Interim CFOAs announced earlier this month, the Company will be appointing a new Chief Financial Officer ("CFO") in the coming weeks. Until such time, following the departure of Dean Larocque as CFO on May 30, 2025, Martina Blahova will serve as interim CFO.About Euro Manganese Euro Manganese is a battery materials company focused on becoming a leading producer of high-purity manganese for the electric vehicle industry. The Company is advancing development of the Chvaletice Manganese Project in the Czech Republic and an early-stage opportunity to produce battery-grade manganese products in Bécancour, Québec.The Chvaletice Project is a unique waste-to-value recycling and remediation opportunity involving reprocessing old tailings from a decommissioned mine. It is also the only sizable resource of manganese in the European Union, strategically positioning the Company to provide battery supply chains with critical raw materials to support the global shift to a circular, low-carbon economy.Euro Manganese is dual listed on the TSX-V and the ASX.Authorized for release by the CEO of Euro Manganese Inc.Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) or the ASX accepts responsibility for the adequacy or accuracy of this release. Enquiries Martina BlahovaChief Executive Officer+1 (604) 681-1010martina@mn25.caLodeRock AdvisorsNeil WeberInvestor and Media Relations - North America+1 (647) 222-0574 neil.weber@loderockadvisors.comJane Morgan Management Jane Morgan Investor and Media Relations - Australia +61 (0) 405 555 618 jm@janemorganmanagement.com.auCompany Address: #709 -700 West Pender St., Vancouver, British Columbia, Canada, V6C 1G8Website: www.mn25.caFollow us on: LinkedIn | Twitter | YouTubeClick Here to Subscribe to our mailing list for updatesForward-Looking StatementsCertain statements in this news release constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company, its Chvaletice Project, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Such statements can be identified by the use of words such as "may", "would", "could", "will", "intend", "expect", "believe", "plan", "anticipate", "estimate", "scheduled", "forecast", "predict" and other similar terminology, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.Readers are cautioned not to place undue reliance on forward-looking information or statements. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company.All forward-looking statements are made based on the Company's current beliefs including various assumptions made by the Company including that the Chvaletice Project will be developed and operate in accordance with current plans, appointment of permanent CFO, that the Company will be able to raise the financing that it requires, and that it will meet conditions of its secured credit facility. Factors that could cause actual results or events to differ materially from current expectations include, among other things: risks and uncertainties related to the Company's ability to meet the conditions of its secured credit facility, risks related to maintaining and securing necessary licenses or permits; risks related to acquisition of surface rights; inability to secure sufficient offtake agreements; the availability of acceptable financing; the potential for unknown or unexpected events to cause contractual conditions to not be satisfied; developments in EV (Electric Vehicles) battery markets and chemistries; and risks related to fluctuations in currency exchange rates, changes in laws or regulations; and regulation by various governmental agencies. For a further discussion of risks relevant to the Company, see "Risk Factors" in the Company's annual information form for the year ended September 30, 2024, available on the Company's SEDAR+ profile at www.sedarplus.ca.Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Subject to applicable securities laws, the Company does not assume any obligation to update or revise the forward-looking statements contained herein to reflect events or circumstances occurring after the date of this news release.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/253771 Copyright 2025 ACN Newswire via SeaPRwire.com.

- ASGH brought together more than 2,900 participants from 42 countries and regions- Medical Fair attracted some 13,000 buyers from 57 countries and regions- The two flagship events together resulted in over 390 deal-making sessions and more than 660 business matching meetings- Collaboration agreements were signed during the events, covering areas including patient care, diagnostic solutions, innovative medical devices, and medical imagingHONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – The fifth Asia Summit on Global Health (ASGH) and the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), both organised by the Hong Kong Trade Development Council (HKTDC), have drawn to a successful close. As flagship events of International Healthcare Week (IHW), both ASGH and the Medical Fair brought global healthcare stakeholders together, including government officials and organisations, research pioneers, investors, and business leaders. ASGH attracted over 2,900 participants from 42 countries and regions, while the Medical Fair received some 13,000 buyers from 57 countries and regions. Over 390 one-on-one deal-making sessions and more than 660 business matching meetings were arranged, facilitating over 1,000 high-quality collaborations and connections. The IHW continues to foster global exchange and cooperation, putting a spotlight on Hong Kong’s vast potential in healthcare investment and trade, and reinforcing its position as a regional leading medical hub.Dr Peter K N Lam, Chairman of the HKTDC, said: "The Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair concluded with outstanding results driving new collaborations and investments, and injecting new momentum into the healthcare industry. The events brought together leaders across government, business, academia, and investment to tackle today’s healthcare challenges, highlighting Hong Kong’s unique advantages as an international innovation and technology hub under its ‘eight centres’ positioning, actively advancing medical technology, connecting global innovation resources, and paving the way for a healthier and more inclusive future."Over 80 industry experts shared insights on healthcare developmentThe two-day ASGH, jointly organised by the HKSAR Government and the HKTDC under the theme ‘Fostering Global Collaboration for a Shared Future’, focused on a wide spectrum of topics including public health, medical technology breakthroughs, healthy ageing and global business and investment collaboration. The event featured more than 80 speakers comprising government officials and organisations, research pioneers, investors, and business leaders from around the world, all contributing valuable insights to advance global well-being.Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech during the Plenary Session I: Shaping a More Equitable and Sustainable Health System. Other distinguished speakers, including Dr Wu Xiaobin, Vice President of China Pharmaceutical Innovation and Research Development Association; Martin Taylor, Representative to China, World Health Organization; Prof Nancy Ip, President of the Hong Kong University of Science and Technology; and Frédéric Rimattei, Special Envoy for International Affairs of the President of French University Hospitals National Association, shared their insights on tackling global healthcare challenges, offering inspiration for the international healthcare community.In Plenary Session II: Fostering Global Collaboration for a Shared Future, speakers engaged in a lively discussion on trends in global healthcare collaboration. Among them was Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan, who remarked that more advanced technology and new government regulations are needed to reach a compromise between companies' profits and patients' needs.During the Dialogue with Global Pioneer in Health session, Prof John Hardy, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, shared his latest research findings and advanced developments in Alzheimer's disease.The summit co-organised sessions under the overarching theme, Shaping the Future of Healthcare, with the Hong Kong University of Science and Technology for the first time. The discussion focused on the potential of AI in healthcare and how innovation could drive breakthroughs in the field. Dr Alex Ng, President of Tencent Healthcare, commented: “One uniqueness of tech companies is that they can be easily distracted by the latest thing. But you do need companies with patience and perseverance to stay in healthcare and make it work.” Prof Graham Cooke, Vice-Dean (Research) Medicine of Imperial College London, also noted that embedding patient needs into healthcare systems is critical, as many innovations fail in translation due to a lack of this focus, with universities playing a key role as innovation drivers.In Beyond ‘Healthy China 2030’: Driving Health Innovation, speakers explored opportunities in the mainland healthcare market. Marc Horn, Executive Vice President of Merck and President of Merck China, highlighted the two-phase approach of "China for China" followed by "China for the globe”, emphasising healthcare collaboration to develop advanced treatments for global benefit. Dr Zhang Lianshan, Executive Vice President of Jiangsu Hengrui Pharmaceuticals Co., Ltd., stated: "We would like to see our health innovation have realisation of its value, not only in China, but also outside of China. That is why we are talking about Globalisation, where we can achieve maximum value."With growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing, Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, and fellow experts explored both the challenges and opportunities posed by ageing populations. Prof Jean Woo highlighted that rapid population ageing is reshaping the global healthcare and socioeconomic landscape. As a city with one of the world’s longest life expectancies, Hong Kong must take early action to strengthen elderly care policies and better allocate health resources. Prof James L. Kirkland also noted that geriatricians ultimately aim to help patients with multiple illnesses reduce medication use while treating their conditions more effectively, enhancing their overall quality of life.Over 390 deal-making sessions and cooperation agreements open new global opportunitiesA key feature of the summit was the ASGH Deal-Making session, which facilitated one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations. Investment projects spanned pharmaceuticals, medical devices and diagnostics, smart healthcare, and community health and wellness and more than 390 one-on-one meetings were successfully arranged for angel investors, venture capitalists, corporate venture arms, private equity firms and family offices.The summit facilitated the signing of cooperation agreements, such as those between Gleneagles Hospital Hong Kong and Emerging Viral Diagnostics, and a tripartite collaboration with PanopticAI and SmartCare, HKSH Medical Group and United Imaging Healthcare, China Resources Guangdong Pharmaceuticals and Hong Kong Medtech Association, Hugobiotech and Bridgeway Healthcare Technology, Canossa Hospital and KA Imaging, and others. These agreements covered diverse healthcare areas, including patient care, diagnostic solutions, innovative medical devices, medical imaging and more. Under the tripartite collaboration agreement between Gleneagles Hospital Hong Kong, PanopticAI, and SmartCare, the integration of PanopticAI’s camera-based vital signs monitoring technology and SmartCare’s patient-centered consultation platform will be implemented into Gleneagles clinic in the future.In addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative technology companies related to the healthcare industry from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand, presenting projects and solutions across key areas such as medical innovation, smart healthcare, AI, big data, telemedicine, and cybersecurity. Zhong Wei, Co-founder of Mitrassist Lifesciences, joined the Shanghai Pavilion and said that ASGH helped them bring non-invasive medical monitoring technologies to Southeast Asia, Africa, and other Belt and Road Initiative countries.Medical Fair Drives Industry Innovation and Fosters Business CollaborationThe Medical Fair, organised by the HKTDC and co-organised by the Hong Kong MedTech Association, was held alongside ASGH. The Association—formerly known as the Hong Kong Medical and Healthcare Device Industries Association—held a renaming ceremony during the fair, showcasing the deep integration of medical technology and the industry.The fair brought together some 300 exhibitors from 13 countries and regions, featuring first-time pavilions from the United Kingdom, Thailand and Israel, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. In addition, seven local universities, over 30 innovative technology companies at the Hong Kong Science and Technology Parks pavilion, and more than 20 medical enterprises brought by the Hong Kong MedTech Association participated. The Hong Kong Council of Social Service also participated in the fair for the first time. Under the theme Innovations Boosting Smart Health Experience, the exhibition spotlighted three major areas: MedTech, GeronTech and green solutions, with many exhibits featuring applications of AI.Many exhibitors and buyers successfully expanded their networks and forged new partnerships at the exhibition. Among them was Hong Kong exhibitor Eieling Technology, a company founded to commercialise research outcomes from the Hong Kong Polytechnic University. The firm showcased its non-invasive liver examination technology, which utilises transient elastography technology. Co-founder and CEO Xiaojia Jia noted that only about four companies worldwide possess this technology, making it a major draw for buyers. "During the exhibition, we received intention orders worth several million Hong Kong dollars from mainland China, Hong Kong, Indonesia, and Thailand, involving around ten devices. This is our third year participating, and we've observed a significant rise in buyers' professionalism during our discussions. We look forward to exhibiting again next year."Karel Lee, CEO of Neoneco from Korea, sourced innovative medical products at the fair with a minimum budget of USD100,000 and he has already identified RhinoCare, an exhibitor from the Israeli pavilion, for its nasal decongestion device, and is also interested in a medical examination device from a Hong Kong exhibitor. Lee stated, "The exhibition allows us to meet with exhibitors face-to-face, build trust, and accelerate the decision-making process. The HKTDC’s Click2Match platform also facilitated efficient business matching. I have already connected with ten exhibitors, and another twenty reached out to me after learning about my sourcing needs. This is one of Asia's premium medical sourcing events, and we will definitely return next year."Beyond business deals, insightful forums were arranged during the Medical Fair to give inspiration to industry buyers. These included The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area, The MedTech Nexus of the Greater Bay Area, co-organised with the Hong Kong MedTech Association, and Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices, co-organised with the HKCSS. These forums attracted a strong attendance and offered valuable insights into healthcare. Selected sessions are available for replay on the Fair’s website for extended engagement.This year’s Fair continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing (hktdc.com Sourcing). Click2Match will remain available until 4 June.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enPhoto download:  https://bit.ly/4kbr9NcThe fifth Asia Summit on Global Health was attended by over 2,900 participants from 42 countries and regionsProf Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech on the first day during the Plenary Session I: Shaping a More Equitable and Sustainable Health SystemProf John Hardy, Chair of Molecular Biology of Neurological Disease at UCL Queen Square Institute of Neurology. As an internationally renowned neurogeneticist, Prof John Hardy has been awarded the Brain Prize for "groundbreaking research on the basis of Alzheimer's disease" and is known as the “father of Alzheimer’s disease genetic studies”. He shared his latest research findings and advanced developments during the Dialogue with Global Pioneer in Health sessionWith growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter for the first time. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing (far left), and fellow experts explore the challenges and opportunities posed by ageing populationsIn addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative solutions from the healthcare industry across 13 countries and regionsASGH Deal-making facilitated over 390 one-on-one meetings(Front row from the left) Dr Kyle Wong, Chief Executive Officer and Co-founder of PanopticAI Limited, Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, and Dr Justin Cheng, Chief Executive Officer and Co-founder of SmartCare Technology Co Limited signed a tripartite cooperation agreement witnessed by (back row from the left) Prof Nancy Ip, President of The Hong Kong University of Science and Technology, Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare and Patrick Lau, Deputy Executive Director of Hong Kong Trade Development CouncilThe 16th Hong Kong International Medical and Healthcare Fair attracted some 13,000 buyers from 57 countries and regions who visited the fair for sourcing and procurementThe Hong Kong MedTech Association had a delegation of over 20 companies participating in the fair, attracting strong interest from buyers who engaged with exhibitors to explore business opportunitiesThe United Kingdom pavilion, participating in the Medical Fair for the first time, promoted innovative medical devices, solutions and services from multiple companies at the fairAn expert from the Greater Bay Area Center for Medical Device Evaluation and Inspection of the National Medical Products Administration; Eva Wong, Senior Electronics Engineer, Medical Device Division of Department of Health (pictured); along with SGS-CSTC Standards Technical Services Co., Ltd.’s expert, shared insights at The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area forumCo-organised by the Hong Kong Council of Social Service, the Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices forum drew a strong turnout from industry professionalsMedia enquiriesFor enquiries, please contact Yuan Tung Financial Relations Limited:Louise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Asia Summit on Global HealthSharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgHong Kong International Medical and Healthcare FairKelly ShekTel: (852) 2584 4537Email: kelly.yt.shek@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic devices provider, announced the successful launch of the 30th Anniversary Celebration and Symposium “Hexallence Beyond 30: Pioneering Tomorrow’s Dentistry” by its Thai subsidiary Hexa Ceram Dental Laboratory (“Hexa Ceram”) in Bangkok, Thailand on 24th May. As a crucial segment of Modern Dental Group's strategic framework in the Asia-Pacific region, Hexa Ceram's 30th anniversary celebration is not only a milestone for the industry but also marks a new starting point for the collaborative development of both parties.In the 30 years since its establishment in 1995, Hexa Ceram has been committed to promoting innovation in dental technology. By 2023, its local market share reached 29%, making it the top dental laboratory in Thailand. It has become a benchmark company in the dental field in Thailand and Southeast Asia. Themed "Pioneering Tomorrow’s Dentistry", this year's celebration aims to review the technological advancements and industry contributions of the brand over the past 30 years, and to open up a forward-looking vision in dentistry for practitioners through insightful discussions with top-tier scholars globally. The symposium specially invited 300 dentists, 100 VIP customers in the industry, dean from 10 top universities and presidents of dental associations to jointly build a blueprint for the future development of dentistry. At this new milestone, Hexa Ceram is dedicated to delivering high-quality and innovative dental solutions and services continuously. It is committed to expanding the presence in the ASEAN Economic Community, fostering growth and excellence in dental care.The global dental industry is currently undergoing an accelerated transformation from traditional models to precision-driven and intelligent approaches. With Hexa Ceram officially incorporated into the global system of Modern Dental Group, the two parties will continue to strengthen their leadership in the Thai market through technological innovation, resource synergy and integration, and effectively promote the Group's competitiveness in the global dental industry value chain. Looking ahead, the Group will continue to maintain its focus on digital innovation as a catalyst and give full play to the strategic role of Hexa Ceram to build a dental ecosystem network in Southeast Asia. Through international technology integration, service model advancements and global resource collaboration, we strive to elevate oral diagnosis and treatment technology in Southeast Asia and globally, delivering transformative dental solutions.About Modern Dental Group Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, and Apex Digital Dental in Malaysia. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 30,000 customers. Copyright 2025 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - May 27, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce the following internal GMG run engine test results when G® Lubricant was added to a Caterpillar 22 kVA diesel engine run at an 80% Load. Test results show a 10% increase in energy efficiency (kwh/litres), and also a 33% reduction in harmful diesel engine exhaust particulate matter emissions, when three doses of G® Lubricant, with a maximum graphene dosage of 0.03%, was added to the standard diesel engine oil.It is noted that the test engine was not operating optimally before G® Lubricant was added - the engine was overheating at long runs of sustained high loads. As a result, after the initial dose of G® Lubricant was added, an additional two dosages of G® Lubricant were used to hopefully bring the engine into a more stable operating regime, an outcome that was generally achieved.Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_gmg_image.jpgBuy Now at: www.G-Lubricant.com Figure 2 and 3 show the table and graph distribution of engine efficiency of the various dosages of G® Lubricant versus the baseline.Baseline Diesel Engine OilEngine Efficiency (kwh/litres)G® Lubricant (0.01%)Engine Efficiency (kwh/litres)G® Lubricant (0.02%)Engine Efficiency (kwh/litres)G® Lubricant (0.03%)Engine Efficiency (kwh/litres)3.043.36 (10% increase)3.35 (10% increase)3.36 (10% increase)Figure 2: Engine Efficiency Performance Increase from G® LubricantFigure 3: % Distribution of Fuel Efficiency Relative to BaselineTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_d626526a342c2ac9_005full.jpgFigures 4 and 5 show the table and graph distribution of diesel engine particulate matter emissions of the various dosages of G® Lubricant versus the baseline.Baseline Diesel Engine OilParticulate Matter (ppm)G® Lubricant (0.01%)Particulate Matter(ppm)G® Lubricant (0.02%)Particulate Matter (ppm)G® Lubricant (0.03%)Particulate Matter (ppm)20.9715.56 (26% reduction)14.55 (31% reduction)13.97 (33% reduction)Figure 4: Engine Emission Particulate Matter Reduction from G® LubricantFigure 5: % Distribution of Particulate Matter in Emissions Relative to BaselineTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_d626526a342c2ac9_006full.jpgFigure 6 shows the exhaust emissions of the diesel engine at various dosages of G® Lubricant, versus the baseline which shows similar levels as the baseline test runs. More testing is being done to get more detail on the impact of G® Lubricant across engine emissions. % O2ppm COppm NO% CO2°C FTppm NOxppm NO2Baseline (DEO)7.8151.5359.69.830.0362.22.7DEO + 1% G® Lubricant7.5161.3383.510.028.1386.73.3DEO + 2% G® Lubricant7.5170.6377.010.027.6379.82.8DEO + 3% G® Lubricant7.4184.8388.710.128.4391.42.7Figure 6: Emissions Data for G® Lubricant Relative to BaselineDetailed Equipment and Process for Testing G® LubricantThe following describes the equipment used and the process followed by the Company in demonstrating the fuel saving demonstration of the G® Lubricant in the diesel engine generator:The same testing equipment, data systems and processes were used which was verified by the University of Queensland and detailed in GMG's previous press release on the 25th February, https://graphenemg.com/gmg-unveils-g-lubricant-engine-performance-testing-results-a-transformative-graphene-energy-saving-solution-for-the-multi-trillion-dollar-global-liquid-fuel-industry/GMG also added the following testing equipment to the testing program:Testo 340 Diesel Kit 2 engine emissions test kit which was newly calibrated by the third-party supplier.PDSA DPM-RT-2 particulate matter test unit which was newly calibrated by the third-party supplier.A 22kVA Caterpillar diesel engine generator (with 1,959 hours of run time) was setup in the GMG Richlands warehouse.The generator was connected to a 40-kW power load bank which consumed the energy produced by the generator and created the load and a 500-litre self-contained fuel tank.Two calibrated flow sensors were connected (inflow and return/outflow) to the fuel lines and to a data logger which recorded the fuel consumption.An Energy Analyzer was used to log and track energy produced by the generator.Tests were conducted on 80% loads of the engine from the 40-kW power load bank - 22 kW.A baseline to record diesel fuel consumption under normal engine oil and operating conditions was completed with newly changed recommended premium diesel engine oil and a new oil filter. This oil change was carried out by a professional engine maintenance service company.The engine was run at 80% load and the baseline and G® Lubricant data set used for the analytics is when the maximum ambient temperature for the day was less than 33 degrees Celsius and relative humidity was between 50% and 80% with no rain. Fuel consumption for diesel engines changes when operating in rain or very high humidity or temperatures, so the fuel consumption data baseline and G® Lubricant engine oil additive performance testing were excluded for these times.Only steady state data was used and so any variance or anomalous data seen in either baseline or G® Lubricant datasets were removed from the analytics. Data sets were grouped into minute blocks.Once the baseline fuel tests were completed, G® Lubricant with approximately 1:100 concentration was mixed at approximately 1% ratio by weight into the existing engine oil. This was done another 2 times. The end ratio of GMG's Graphene to the diesel engine oil was approximately 3:10,000 by weight.GMG's Managing Director and CEO, Craig Nicol, commented: "G® Lubricant is not only increasing fuel efficiency it is also reducing particulate matter - which is amazing to see - we will need to do more tests to see what the long-term performance is for this."GMG is continuing to conduct more tests to determine the total performance regime of the G® Lubricant. These performance tests will be announced as the information becomes available.GMG's Chairman and Director, Jack Perkowski, commented: "Fantastic news - G® Lubricant testing data are exciting - well done to the team - showing great promise as a way to reduce fuel costs and emissions across the multi-trillion dollar liquid fuels industry."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the potential of G® Lubricant to optimize efficiency and power for stationary or mobile engines, the potential of G® Lubricant to reshape the future of the global liquid fuels industry, GMG's intention to commercialise and market G® Lubricant, the progress of the Company's patent applications, the potential market for G® Lubricant and the potential revenue available for G® Lubricant.Such forward-looking statements are based on a number of assumptions of management, including, without limitation that G® Lubricant has the potential to optimize efficiency and power for stationary or mobile engines, that G® Lubricant has the potential to reshape the future of the global liquid fuels industry, that GMG will commercialize and market G® Lubricant, that the Company's patent applications will progress as anticipated, and that the potential market and revenue available for G® Lubricant will be as currently forecasted. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that G® Lubricant will not offer an innovative solution that optimizes efficiency and power for stationary or mobile engines, that G® Lubricant will not reshape the future of the global liquid fuels industry, that GMG will commercialize and market G® Lubricant as anticipated, that the Company's patent applications will not progress as currently anticipated, that the potential market and revenue available for the G® Lubricant product is not as currently calculated, risks relating to the extent and duration of the conflict in Eastern Europe and its impact on global markets, the volatility of global capital markets, political instability, the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel, unexpected development and production challenges, unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253490 Copyright 2025 ACN Newswire via SeaPRwire.com.

KUALA LUMPUR, May 27, 2025 - (ACN Newswire via SeaPRwire.com) - CGS International Securities Pte Ltd (“CGS International”) and CGS International Securities Malaysia Sdn Bhd (“CGS MY”) in collaboration with MBSB and OCBC Malaysia, today at their curtain raiser for the inaugural ASEAN Business Forum 2025 (“ABF2025” or the “Forum”), shared key action points slated for intense discussion at the event to be held on 29 May 2025. ABF2025 will be held in conjunction with the 46th ASEAN Summit 2025 in Kuala Lumpur, and the ASEAN-GCC + China Summit 2025. A key highlight of the forum is the corporate engagement and business exchange session designed to drive real business collaboration between pre-screened and pre-selected matching parties from the top 25 corporations and investors across ASEAN and China.From left to right: En. Khairi Shahrin Arief Baki, Deputy CEO of CGS MY, Mr. Sivasuriyamoorthy Sundara Raja, Deputy CEO of MIDA (Investment Promotion and Facilitation), Puan Azizah Mohd Yatim, CEO of CGS MY, YBhg. Tan Sri NazirRazak, Chairman of the ASEAN-BAC for Malaysia, Ms. Tan Ai Chin, Managing Director, Senior Banker & Head of Investment Banking of OCBC Malaysia, YBhg. Dato' Azlan Shahrim, Group Chief Strategy Officer of MBSB Berhad, and Mr. Alan Inn Wei Loon, Deputy CEO of CGS MY at the Curtain Raiser for the ASEAN Business Forum 2025.Themed “From Vision to Reality – ASEAN Partnerships Fuelling Sustainable Growth”, the forum is co-hosted with the Malaysian Investment Development Authority (MIDA) and ASEAN Business Advisory Council (ASEAN-BAC) Malaysia. It is expected to draw more than 600 attendees comprising over 200 foreign and local corporates, policymakers and corporate captains. They represent the region’s largest companies of over RM1 trillion in market capitalisation, council members of ASEAN BAC countries, and fund managers with total funds under management of over RM 8 trillion. The gathering comes at a critical juncture of a changing world order arising from United States tariffs, as affected countries explore alternative strategies to sustain economic stability and growth.Present at the curtain raiser were CGS International’s strategic partners, represented by YBhg. Tan Sri Nazir Razak, Chairman of the ASEAN-BAC for Malaysia, Mr. Sivasuriyamoorthy Sundara Raja, MIDA Deputy Chief Executive Officer (Investment Promotion and Facilitation), YBhg. Dato’ Azlan Shahrim, Group Chief Strategy Officer representing MBSB Berhad and Ms. Tan Ai Chin, Managing Director, Senior Banker & Head of Investment Banking of OCBC Malaysia – both trusted banking partners committed to growing ASEAN financial ecosystems and supporting sustainable investment flows.Mr. Sivasuriyamoorthy Sundara Raja, MIDA Deputy CEO (Investment Promotion and Facilitation) shared, “We commend CGS International Securities for hosting the ASEAN Business Forum 2025 — a timely effort that speaks to the region’s shared aspiration for sustainable and inclusive prosperity, amidst geopolitical and challenging global economic landscape. At MIDA, we are committed to partnerships that go beyond transactions, that shape long-term value for Malaysia and uplift business communities. This forum bodes well with the statement of intent by ASEAN — to lead with shared purpose, unity, and economic vision. As the Malaysian government’s principal promotion agency, MIDA stands ready to facilitate investments that strengthen regional supply chain integration and elevate ASEAN on the global stage.”YBhg. Tan Sri Nazir Razak, Chairman of the ASEAN-BAC for Malaysia added, “Now, more than ever, ASEAN needs to strengthen bilateral ties and stay united. We need to be deliberate and realistic, taking concerted efforts to optimise intra-ASEAN trade and investments. Amongst our 12 priorities, initiatives such as the ASEAN Business Entity (ABE) directly facilitate this by enabling operational flexibility to ASEAN-based companies to move business, capital, and talent, which will in turn allow emerging businesses and markets to flourish.”In her opening presentation, Puan Azizah Mohd Yatim, CEO of CGS MY said, “This forum marks a major milestone in our ongoing efforts to attract more investment and trade to the region by leveraging CGS International Group’s Chinese parentage. Malaysia’s Chairmanship of ASEAN is happening at a unique time of a shifting world economy. Together with our fellow ASEAN members, we have a golden opportunity to co-ordinate and re-establish deeper, stronger intra-ASEAN, ASEAN+3 and global ties. Through our deep ASEAN network and parentage, we can connect and support the capital needs of businesses in the region and help investors navigate cross-border investments confidently. To date, we have organised and facilitated B2B and B2G engagements for companies and policymakers with China, working towards uplifting ASEAN’s businesses and economies.”On behalf of MBSB Group, its Chief Strategy Officer Dato’ Azlan Shahrim highlighted, “Our active participation in the ASEAN Business Forum reflects our commitment to catalysing deeper collaboration across the region. At MBSB Group, we are committed to advancing Malaysia’s regional and global ambitions through our unique combination of MBSB Bank’s banking solutions and MIDF’s development finance expertise. With focus on high-impact sectors such as renewable energy, electrical and electronics, aerospace, agri-foods, and halal, we provide bespoke services that empower businesses and SMEs to grow strategically across ASEAN and beyond. Through our investment banking services, Shariah advisory expertise, and commitment to sustainability, we are helping companies raise capital and scale, in line with the region’s evolving economic landscape.”Ms Tan Ai Chin, Managing Director, Senior Banker & Head of Investment Banking of OCBC Malaysia, concluded, “At OCBC, we believe ASEAN’s strength lies in its connectivity — the seamless integration of markets, talent, and capital, underpinned by sustainable growth. Our participation in ABF2025 underscores our commitment to facilitate cross-border economic collaboration. Through OCBC Group’s integrated global network – spanning corporate & investment banking, private banking, asset management and insurance – we empower businesses to unlock growth opportunities that transcend borders. With our deep-rooted presence in ASEAN and Greater China, OCBC is uniquely positioned to deliver tailored sustainable and Islamic financial solutions as well as bespoke M&A advisory to facilitate trade and investment flows. Together, we are bridging economies while building a resilient, net-zero future for ASEAN.”The full-day forum will feature more than 20 speakers and panellists for discussions as well as closed- door meetings between investors and policy makers, all focused on addressing challenges and catalysing opportunities for high-value deals and strategic partnerships for regional economic growth. Several memoranda of understanding (MOUs) will be announced during the Forum, signalling long- term collaboration in strategic growth sectors such as healthcare, investments, single family office, and trade. In addition to the MOUs, China Galaxy Securities and CGS International Group intend to establish a China-Malaysia and ASEAN investment programme, which aims to foster capital flows, build stronger investment linkages, and support co-investment opportunities amongst China, Malaysia and ASEAN countries, with Malaysia as a key regional anchor. Copyright 2025 ACN Newswire via SeaPRwire.com.

AI-powered real-time deepfake detection solution, Aletheia, recognised for effectiveness, innovation, and operational scalabilityHONG KONG, May 27, 2025 - (ACN Newswire via SeaPRwire.com) - Ensign InfoSecurity (“Ensign”), one of Asia’s largest cybersecurity service providers, has won the “Product Excellence - Cybersecurity Product of the Year” award at the Tech Fest Hong Kong Awards 2025 for its proprietary solution, *Aletheia, an AI-powered real-time deepfake detection tool that enhances digital trust and protects organisations against multimedia-based deception.Developed by Ensign Labs, Aletheia uses multi-modal artificial intelligence to identify manipulated video and audio content. Available across endpoint software or a chrome browser plug-in, the solution delivers real-time detection to support secure virtual meetings, digital identity verification, and high-assurance communication environments.Built for operational environments, Aletheia performs all detection on-device, ensuring privacy-first analysis without cloud dependency. It integrates seamlessly with Security Information and Event Management (SIEM) systems to provide real-time alerts, enabling security teams to respond swiftly with forensic-ready evidence for investigation and resolution.“This award reinforces the purpose behind our work,” said Nicky Au, General Manager, Greater China Region, Ensign InfoSecurity (East Asia) Limited. “As threats grow more sophisticated, the ability to safeguard digital interactions, authentically and at speed, has become critical to business resilience and public trust.Cybersecurity is not achieved in isolation. It requires coordination, transparency, and shared intelligence. At Ensign, we are committed to working alongside our peers, partners, and clients to stay ahead of what’s next.”Aletheia is built to meet the evolving needs of sectors most vulnerable to digital deception. Examples of its use are varied. In financial services, it adds a line of defence during voice authentication and transaction validation. For media organisations, it supports source verification and editorial integrity. Government agencies can rely on it to validate emergency communications, while Human Resource departments use it to screen for audio-visual fraud in remote interviews and recruitment processes.This award underscores Ensign’s commitment to developing applied, scalable technologies through its in-house R&D. Aletheia is part of a broader portfolio of AI-powered capabilities that include cyber analytics, digital risk monitoring, and automated threat detection, designed to equip enterprises and public institutions with future-ready defence strategies.*Aletheia, in Greek mythology, refers to the Goddess of truth, symbolising the pursuit of truth and transparency.About Ensign InfoSecurityEnsign InfoSecurity is the largest cybersecurity service provider in Asia. Headquartered in Singapore, Ensign offers bespoke solutions and services to address their clients’ cybersecurity needs. Their core competencies are in the provision of cybersecurity advisory and assurance services, architecture design and systems integration services, and managed security services for advanced threat detection, threat hunting, and incident response. Underpinning these competencies is in-house research and development in cybersecurity. Ensign has two decades of proven track record as a trusted and relevant service provider, serving clients from the public and private sectors in the Asia Pacific region.For more information, visit www.ensigninfosecurity.com, or email media@ensigninfosecurity.com Copyright 2025 ACN Newswire via SeaPRwire.com.

- The Asia Summit on Global Health (ASGH) gathers over 80 government officials and organisations, research pioneers, investors, and business leaders to explore international collaboration on medical technology, silver health, and healthcare systems. A dedicated “Silver Health Chapter” debuts this year to spotlight the ageing population.- Renowned speakers include Prof John Hardy, the “father of Alzheimer’s disease genetic studies”; Dr Victor Yosef Melt Campos, Chair (2024-2025) of APEC Health Working Group and General Director of International Cooperation at the Ministry of Health of Peru; and Martin Taylor, Representative to China of the World Health Organization. They will share insights on the latest developments in medical innovation.- The Hong Kong International Medical and Healthcare Fair (Medical Fair) focuses on MedTech, GeronTech, and green solutions, featuring the latest medical health devices, products, and solutions including many AI-powered innovations.- The Medical Fair has attracted some 300 exhibitors from 13 countries and regions. Participating with pavilions for the first time are Israel, Thailand, and the UK, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg.HONG KONG, May 26, 2025 - (ACN Newswire via SeaPRwire.com) – International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), officially opened today. One of its flagship events, the fifth Asia Summit on Global Health (ASGH), takes place today and tomorrow (26 and 27 May) at the Hong Kong Convention and Exhibition Centre (HKCEC). Under the theme Fostering Global Collaboration for a Shared Future, the summit brings together more than 80 healthcare leaders and experts from around the world to explore the future direction of the industry and collaboration opportunities. Another flagship event, the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), also kicks off today (26 to 28 May), and features some 300 exhibitors from 13 countries and regions, showcasing cutting-edge MedTech, GeronTech, and green solutions, including many AI-powered innovations, to foster global industry collaboration.The ASGH opened with welcome remarks delivered by HKTDC Chairman Dr Peter K N Lam.  “The global health sector is currently facing challenges, including a resurgence in infectious diseases, coupled with the growing needs of an ageing population and ongoing health equity concerns. These issues demand urgent attention and collective action to protect communities worldwide. Now in its fifth edition, ASGH is a key event for the global healthcare industry, and we are proud that connections made through ASGH have enabled many new investments and collaborations in healthcare innovation. Alongside ASGH, the Hong Kong International Medical and Healthcare Fair is taking place. There, you will find the latest HealthTech solutions from around the globe, with a particular focus on hospital equipment, rehabilitation, elderly care and biotech. As anchor events of the International Healthcare Week, ASGH and Medical Fair highlights Hong Kong’s commitment to working with partners to nurture an innovative health and medical sector,” Dr Lam said.In his opening speech, Hong Kong SAR Chief Executive John Lee said: "Under the theme of "Fostering Global Collaboration for a Shared Future", this summit reaffirms Hong Kong's pivotal role as a leading health innovation hub in the region. Under the "one country, two systems" principle, Hong Kong enjoys unique connectivity with both Mainland China and the world. As the world's freest economy and one of the top three international financial centres, we offer an efficient, open and fair business environment with robust intellectual property protection. We maintain free flows of information, capital, goods and talent. We are also emerging as a leading hub for scientific innovation, technological advancement and world-class education.”Prof Cao Xuetao, Vice-Minister of the National Health Commission of the People’s Republic of China, gave special remarks, noting: "China continues to open up and welcomes leading foreign-owned hospitals into the market through investment or joint ventures. We hope that our global partners can further localise and upgrade their mid-to-high-end products, resulting in win-win outcomes for all.”Additionally, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), delivered remarks at the opening session via video link and stated, “The theme of ASGH could not be more appropriate given the challenges facing global health at the moment. The WHO Pandemic Agreement has been adopted recently. It was negotiated over the past three and a half years and shows a true spirit of international collaboration for global health. By working together, we can build a healthier, safer, and fairer world for all.”Global industry leaders gather to explore opportunities for international collaborationToday's Plenary Session I: Shaping a More Equitable and Sustainable Health System, featured keynote remarks by Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, and Feng Haicang, Level I Bureau Rank Official of Department of Consumer Goods Industry, Ministry of Industry and Information Technology of the People's Republic of China.  Prof Lo Chung-mau, stated: “A sustainable health system requires talents and enough healthcare manpower. While the Government has been addressing the issue of manpower shortage through a multipronged strategy, by increasing the number of intakes for local universities and admitting qualified non-locally trained healthcare workers, the 2024 Policy Address announced that the Government supports the plan to establish a third medical school. Indeed, Hong Kong has already hosted two top 30 world class medical schools but we have the ability and the need to develop the third one which shall adopt an innovative strategic positioning in pursuit of complementary development with the two existing ones.” The session was moderated by Prof Tsui Lap-chee, Chairman of the University of Hong Kong Foundation for Educational Development and Research, focused on key issues faced by healthcare systems in addressing global challenges. Distinguished speakers included Martin Taylor, Representative to China of the WHO; and Prof Nancy Ip, President of the Hong Kong University of Science and Technology. They shared valuable experiences and forward-looking insights to inspire the global healthcare field.Prof Nancy Ip noted: “Universities are more than academic institutions. They are global connectors, neutral platforms, and also engines of innovation, uniquely positioned to bridge divides between disciplines, industries, and also nations.”Distinguished international speakers of Plenary Session II: Fostering Global Collaboration for a Shared Future included Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan. They jointly explored trends in global healthcare collaboration, injecting new ideas into constructing a more synergistic global healthcare landscape.The summit invited Prof John Hardy, known as the “father of Alzheimer’s disease genetic studies”, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, to share his outlook on future research and treatment of neurodegenerative diseases such as Alzheimer's in the Dialogue with Global Pioneer in Health session.Prof John Hardy remarked: “For Alzheimer's treatment, I think that two changes can happen quite quickly: improvements in earlier diagnosis, and development of drugs that bypass the blood vessel-based amyloid. What we want to do with drugs is slow decline. If we understand what underpins that decline, it gives us targets, and we’re very excited by some of the findings in that area now.”“Healthy China 2030” serves as the national blueprint for healthcare policy development in Mainland China. In the session Beyond “Healthy China 2030”: Driving Health Innovation, Dr Zhang Lianshan, Executive Vice President, Jiangsu Hengrui Pharmaceuticals Co., Ltd.; and Marc Horn, Executive Vice President of Merck and President of Merck China, explored opportunities in the mainland healthcare market, analysing emerging trends in China's healthcare innovation ecosystem to open new pathways for international collaboration with other speakers.Diverse topics converge with forward-looking insights and the Silver Health Chapter explores new business opportunitiesFor the first time, the summit co-organised two thematic sessions with the Hong Kong University of Science and Technology under the overarching theme Shaping the Future of Healthcare. Speakers included Prof Graham Cooke, Vice-Dean (Research) of Faculty of Medicine at Imperial College London. They focused on the potential of AI in the medical field, sharing with participants how innovative technologies are driving new breakthroughs in healthcare. Additionally, sessions on Peeking into the Future of Gene and Cell Therapies and Women’s Health in Focus were also closely aligned with global medical development trends.Continuing today's in-depth dialogues, more exciting sessions will be presented tomorrow. For the first time, the summit will feature a Silver Health Chapter focusing on addressing the challenging ageing societies. Speakers including Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, will gather at tomorrow morning's session Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology to delve into how to address the challenges brought by an ageing population, analysing future development trends and potential investment opportunities in the silver economy market.Furthermore, globally renowned speakers will be present tomorrow to share their valuable experiences and insights. Wyman Li, Chief Operating Officer of HKSH Medical Group; Prof Karim Asehnoune, President of National Committee for Public Hospital Research (CNCR), and other speakers will analyse how to promote the sustainable development of the healthcare industry through collaboration among different stakeholders in the session, Reinventing the Business of Healthcare through Partnerships. Prof Xu Hongxi, Distinguished Professor and Honorary Dean of Shanghai University of Traditional Chinese Medicine and other guests will discuss the latest developments and commercial potential of integrating Chinese and Western medicine in the session The Convergence of Chinese and Western Medicine in Global Health. Sessions on The Next Wave of Innovations in Neuroscience, Data-driven Healthcare Transforming Patient Journey and The Changing Face of Cancer will also be held tomorrow.A global platform for healthcare resource matchmaking to foster opportunities for innovative collaborationIn addition to thematic discussions, the summit also aims to bridge global collaboration among participants. For example, the ASGH Deal-making facilitates one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations.The summit has established the ASGH Business Hub, which brings together more than 170 innovative technology companies and award-winning projects from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand. The InnoHealth Showcase serves as a platform to explore business opportunities and innovative solutions and highlights more than 70 healthcare start-ups and projects led by the Innovation and Technology Commission, Cyberport, and six local universities. The showcase is structured around four key categories: pharmaceuticals and therapeutics, AI and Digital Health, medical devices and diagnostics, and community health and wellness. As part of the “Silver Health Chapter”, some of the showcased projects address the challenges of an ageing population, including early blood tests for Alzheimer’s disease, demonstrating cutting-edge capabilities and market potential in elderly healthcare.Integrating global innovations to showcase the future of healthcareThe Hong Kong International Medical and Healthcare Fair also opened today, organised by the HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA). Under the theme Innovations Boosting Smart Health Experience, this year’s Fair focuses on three key areas: MedTech, GeronTech and green solutions, featuring the latest medical health devices, products, and solutions.In the field of MedTech, UK exhibitor London Medical Exchange (Booth No: 3F-H15) presents a fully automated AI-powered patient monitoring system designed to improve patient care, transforming healthcare from reactive to proactive. Meanwhile, C2iTech (Booth No: 3F-G04), established by a research team from the School of Public Health at The University of Hong Kong, showcases a Respiratory Organoid Platform (ROP). By analysing nasopharyngeal or throat saliva samples from individuals, the platform predicts their likely response to respiratory virus infections, enabling more precise and personalised treatment by healthcare professionals.In the GeronTech segment, Medmind Technology (Booth No: 3F-G04), from the Hong Kong Science and Technology Parks Corporation (HKSTP) Pavilion, introduces an app for cognitive impairment assessment. The tool allows middle-aged and elderly users to play digital mahjong and other games, with AI used to assess their cognitive status and offer personalised brain training, helping prevent and detect early signs of cognitive decline. The system can also monitor patient conditions over time.The Hong Kong Council of Social Service (HKCSS), participating in the fair for the first time, is showcasing a range of GeronTech and related products, covering areas such as rehabilitation and mobility assistance, cognitive impairment support for patients and carers, and smart home solutions. HKCSS is also introducing its GeronTech education and rental services, along with its online platform that enables the public to learn about and hire GeronTech equipment. Users such as the elderly, people in rehabilitation, and carers can try out products, and rent or purchase them as needed, with support from a cross-disciplinary professional team. Through the Medical Fair, HKCSS aims to attract collaboration with other businesses to expand its services and benefit a wider segment of the community.For green solutions, MassPhoton (Booth No: 3F-H18), also from the HKSTP Pavilion, presents an ultraviolet disinfection system that combines semiconductor and smart control technologies, delivering more efficient and energy-saving disinfection for air, water and surfaces.This year’s Medical Fair has attracted some 300 exhibitors from 13 countries and regions. Participating with pavilions for the first time are Israel, Thailand, and the UK, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. Highlighting Hong Kong’s strength in medical innovation, seven local universities, over 30 innovative technology companies at the HKSTP pavilion, and more than 20 medical enterprises brought by the HKMHDIA are participating.The exhibition features a range of thematic zones, including Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care Products, and Start-up and HKMHDIA zones.  Highlight exhibits include AI-powered rehabilitation systems, portable ultrasound diagnostic systems, and smart hospital robots, demonstrating the frontiers of medical and healthcare technology.During the Medical Fair, there will be forums, seminars and networking receptions. Two forums focused on the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) healthcare sector will take place tomorrow. The morning forum titled The MedTech Nexus of the Greater Bay Area, which is co-organised with the HKMHDIA, will feature industry experts sharing insights on intellectual property strategies for biomedical innovation, ways to integrate resources for GBA market development, and successful experiences in promoting medical technology in the GBA. The afternoon forum titled The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area will bring together experts from the Greater Bay Area Centre for Medical Device Evaluation and Inspection of National Medical Products Administration, the Medical Device Division of Department of Health, and SGS-CSTC Standards Technical Services Co., Ltd., to explore the latest developments, administrative systems and regulations in relevant fields, promoting cross-regional regulatory collaboration and fostering innovation through idea exchange.Using the HKTDC EXHIBITION+ hybrid model, global exhibitors, industry professionals, and buyers can continue business matching via the Click2Match smart business matching platform until 4 June, encouraging more cooperation.Aside from ASGH and the Medical Fair, IHW also features the Hospital Authority Convention, among many other industry events.Photo download: https://bit.ly/43xCK2bThe fifth Asia Summit on Global Health, jointly organised by the Hong Kong SAR Government and the Hong Kong Trade Development Council takes place at the Hong Kong Convention and Exhibition Centre from 26 to 27 May 2025 under the theme Fostering Global Collaboration for a Shared FutureDr Peter K N Lam, HKTDC Chairman, gives a welcome addressJohn Lee, Chief Executive of the Hong Kong SAR, delivers opening remarksProf Cao Xuetao, Deputy Director of the National Health Commission of the People’s Republic of China, delivers special remarksDr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organisation, delivers remarks at the opening session via video linkThe summit invites Prof John Hardy, Chair of Molecular Biology of Neurological Disease at UCL Queen Square Institute of Neurology. As an internationally renowned neurogeneticist, and Brain Prize recipient for "groundbreaking research on the basis of Alzheimer's disease", Prof John Hardy is known as the “father of Alzheimer’s disease genetic studies”ASGH deal-making facilitates one-on-one meetings both online and offline, aiming to bridge investors with healthcare projects from around the world and promote global collaborationASGH facilitates the signing of the partnership agreements, fostering concrete collaboration in various areas of the healthcare industry.The 16th Hong Kong International Medical and Healthcare Fair, themed Innovations Boosting Smart Health Experience, focuses on three key areas: MedTech, GeronTech and green solutions, featuring the latest medical health devices, products, and solutionsMedmind Technology, from Hong Kong Science and Technology Parks Corporation (HKSTP) Pavilion, introduces an app for cognitive impairment assessment. The tool allows middle-aged and elderly users to play digital mahjong and other games, with AI used to assess their cognitive status and offer personalised brain training, helping prevent and detect early signs of cognitive declineThe Hong Kong Council of Social Service (HKCSS), participating in the fair for the first time, showcases a range of GeronTech products, covering areas such as rehabilitation and mobility assistance, cognitive impairment support for patients and carers, and smart home solutionsThe Hungarian pavilion is once again participating in the Medical Fair, bringing devices for health assessment and medical-related coursesWebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enProgramme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programmeSpeakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speakerHong Kong International Medical and Healthcare Fair:https://www.hktdc.com/event/hkmedicalfair/enList of products: https://www.hktdc.com/event/hkmedicalfair/en/productActivity schedule: https://www.hktdc.com/event/hkmedicalfair/en/intelligence-hubMedia enquiriesFor enquiries, please contact Yuan Tung Financial Relations Limited:Louise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Asia Summit on Global HealthSharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgHong Kong International Medical and Healthcare FairKelly ShekTel: (852) 2584 4537Email: kelly.yt.shek@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Kuala Lumpur, May 26, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (“CBL” or the “Company”), the listing vehicle of Banle Group (“Banle” or the “Group”), a leading marine fuel logistics company in the Asia-Pacific region, today announced the official renaming of its Singapore-based wholly owned subsidiary, Majestic Energy (Singapore) Pte Ltd, to support its regional growth strategy.Effective immediately, Majestic Energy (Singapore) Pte Ltd has been officially renamed to Banle International (Singapore) Pte Ltd, reflecting the Group’s deepening commitment to the Singapore market and its strategic expansion into sustainable fuels.Singapore remains the world's largest bunkering hub, with annual sales close to 55 million metric tons in 2024, increased by 6% year-over-year as compared to 2023, according to Maritime & Port Authority of Singapore (“MPA”) statistics. While conventional fuels still dominate the market, demand for sustainable fuels such as biofuels, LNG, and methanol continues to rise steadily. Notably, biofuel sales in the first four months of 2025 in Singapore have already surpassed 50% of the total volume recorded in 2024, according to  MPA statistics.As the primary fuel bunkering hub in the Asia-Pacific region, Singapore serves as a strategic base for CBL’s regional expansion. CBL’s revenue in Singapore increased by 102% year-over-year in 2024 as compared to 2023. In March 2025, the Company launched its first biofuel supply services in Singapore — a key regional port — as part of its broader initiative to offer sustainable fuel alternatives across the region, followed by biofuel supply in Malaysia, Hong Kong and various ports in China. CBL’s biofuel sales volumes and sales surged over 600% year-over-year in 2024, supported by strengthened supplier relationships and reliable supply chains. These efforts help customers meet IMO GHG targets while offering sustainable, cost-effective alternatives.“Singapore plays a pivotal role in our long-term growth strategy,” said Dr. Teck Lim Chia, Chairman and CEO of CBL. “The renaming of our subsidiary underscores our strengthened presence in this critical market and reinforces our commitment to supporting the global maritime industry’s transition toward greener energy solutions.”Despite the increasing competition in Singapore’s bunkering sector, CBL continues to differentiate itself through its agile operations and customer-centric approach. The Company prides itself on its ability to adapt and tailor solutions to meet the specific needs of clients and suppliers, enabling it to capture new opportunities in both traditional and emerging fuel segments.Christofel Tian, our Head of Singapore, added "With our rebranding to Banle International (Singapore) Pte Ltd, we are not only aligning ourselves more closely with the Group’s identity but also signaling our long-term commitment to the Singapore market. As the global bunkering landscape evolves, especially with the rapid adoption of sustainable fuels, we are well-positioned to grow alongside Singapore’s vision of becoming a leader in sustainable maritime solutions."With its robust regulatory environment, mature infrastructure, and strong government support, Singapore is well-positioned to maintain its leadership in the global bunkering market — and CBL is committed to growing alongside it.About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistic company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in over 60 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam, as of 16 April 2025. The Group actively promotes the use of sustainable fuels and is awarded with the ISCC EU and ISCC Plus certifications.For more information about our company, please visit our website at: https://www.banle-intl.com.Forward-Looking StatementsCertain statements in this announcement are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” “should,” “would,” “plan,” “future,” “outlook,” “potential,” “project” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. They involve known and unknown risks and uncertainties and are based on various assumptions, whether or not identified in this press release and on current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, markets, financial, political and legal conditions, geopolitical disruptions and other events that result in material changes in fuel prices. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.CBL INTERNATIONAL LIMITED (Incorporated in Cayman Islands with limited liabilities)For more information, please contact: CBL International Limited Email: investors@banle-intl.comStrategic Financial Relations LimitedShelly Cheng        Tel: (852) 2864 4857 Iris Au Yeung       Tel: (852) 2114 4913 Email:              sprg_cbl@sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

BRATISLAVA, May 26, 2025 - (ACN Newswire via SeaPRwire.com) - The Council of Slovak Exporters welcomes the launch of the European Commission’s public consultation, announced in early May, focused on potential response measures regarding certain imported goods from the United States, should ongoing discussions on transatlantic economic cooperation not lead to a mutually beneficial outcome. Topics under consultation may include trade flows in sectors such as steel scrap and chemical products. The consultation will close on 10 June, coinciding with the Visegrad 4 Business Conference in Bratislava, where regional business leaders will convene to address global economic relations, EU market resilience, and other key issues critical to regional competitiveness."It is indeed symbolic that these consultations with the European Commission, which represent a much-needed link between the private and public sectors, are culminating on the day of our Visegrad 4 Business Conference, which aims to do exactly the same: To achieve demand-driven public policies and measures that will help Europe's industry and exports from losing global competitiveness." – said Lukáš Parízek, founder of the Visegrad 4 Business Conference and Chairman of the Council of Slovak Exporters.Top industry representatives from various sectors, as well as public officials and representatives of foreign diplomatic missions, have already confirmed their participation in this key regional business event. The conference, organized in the premises of the Bratislava Castle, will be opened with a speech by the Speaker of the Parliament Richard Raši. Maros Sefcovic, European Commissioner for Trade and Economic Security, will deliver his remarks and speak in an exclusive format during the first part of the day, as well as attend a roundtable discussion with industry leaders from the V4 region. Slovak Foreign Minister Juraj Blanár and Hungarian Foreign Minister Péter Szijjártó have also confirmed their participation in the closing part of the conference.Visegrad 4 Business Conference is jointly organised since 2022 by four business organisations from the V4 region: Council of Slovak Exporters, Czech Association of Exporters, Hungarian business association MAPI Klub and Polish Economic Forum. The conference is organised with the support of the International Visegrad Fund, individual V4 governments and private sponsors.For more information visit www.visegrad4business.eu.About the Council of Slovak ExportersThe Council of Slovak Exporters was established in 2020 as a response to COVID-19's impact on local businesses. With over 130 supporting companies, this business platform connects exporters and facilitates dialogue with state institutions, international organizations, and financial institutions. The Council publicly communicates in support of Slovak exporters, provides export-related assistance, organizes networking events, and connects relevant entities in international trade. The organization holds BRONZE "European Cluster Excellence Initiative" certification, operating at the European level.Social LinksX: https://x.com/Visegrad4BInstagram: https://www.instagram.com/visegrad4business/LinkedIn: https://www.linkedin.com/company/visegrad-4-business/Facebook: https://www.facebook.com/visegrad4business#Media ContactCouncil of Slovak ExportersVisegrad 4 Business Conference+421 914 201 101https://www.visegrad4business.eu/ Copyright 2025 ACN Newswire via SeaPRwire.com.

ADELAIDE, AUS, May 26, 2025 - (ACN Newswire via SeaPRwire.com) - Eastern River, a leading Australian bond brokerage, is set to expand its investment platform with the introduction of Bond Exchange-Traded Funds (ETFs) and the upcoming launch of a new fixed-income fund. These developments represent a significant step forward in improving access to institutional-grade bond strategies for both private and wholesale investors.The addition of Bond ETFs will provide clients with an efficient and liquid route to diversified fixed-income exposure, encompassing government, corporate, and ESG-focused debt instruments. This move reflects Eastern River's continued commitment to delivering cost-effective, transparent solutions in a dynamic yield environment."We are introducing Bond ETFs to offer clients a more flexible and streamlined means of accessing the fixed-income market," said Mrs Sally Peters, Public Relations Officer at Eastern River. "The new fixed-income fund will further support this initiative by offering a stable, actively managed option focused on capital preservation and consistent yield."Scheduled to launch in Q4, the fund is designed to meet growing demand for reliable income amid ongoing interest rate uncertainty. It will leverage Eastern River's proven expertise in credit research, yield targeting, and risk management.Both the Bond ETFs and the new fund will be managed within Eastern River's active oversight framework, which prioritises downside protection and disciplined portfolio construction. Clients will benefit from improved market access, enhanced liquidity, and tailored strategies to suit evolving market conditions.These initiatives reinforce Eastern River's position as a forward-thinking bond specialist, dedicated to helping investors navigate today's market with clarity and confidence.For more information on Eastern River's forthcoming Bond ETF range and fixed-income fund, visit https://easternriver.com or contact media@easternriver.com.SOURCE: Eastern River Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com.